News
AZ’s oncology hopes dented as Imfinzi flunks NSCLC trial
AstraZeneca’s cancer immunotherapy Imfinzi broke new ground when it was approved in 2018 for locally advanced non-small cell lung cancer (NSCLC) that can’t be treated with
